Asusi, Gwendoline .

HRN: 26-26-72  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/29/2024
CEFUROXIME 1.5GM (VIAL)
11/29/2024
11/30/2024
IV
1.5gm
Q8
T/c Phlebitis
Waiting Final Action 
11/29/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
11/29/2024
12/06/2024
IV
900mg
Q8
Endometritis
Waiting Final Action 
11/29/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
11/29/2024
12/06/2024
IV
300mg
OD
Endomet
Waiting Final Action 
11/30/2024
AMPICILLIN 1GM (VIAL)
11/30/2024
12/06/2024
IV
2 G
Q6
T/c Endometritis
Waiting Final Action 
12/01/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/01/2024
12/07/2024
IV
500 Mg
Q8
HAP Tc Endometritis
Waiting Final Action 
12/01/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
12/01/2024
12/07/2024
IV
4.5
Q8
HAP
Waiting Final Action 
12/01/2024
LEVOFLOXACIN 500MG (TAB)
12/01/2024
12/07/2024
ORAL
500 Mg
OD
CAP
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: